Efficacy of clarithromycin against H5N1 and H7N9 avian influenza a virus infection in cynomolgus monkeys.
暂无分享,去创建一个
Y. Kawaoka | M. Le | Takeshi Shimizu | Y. Itoh | K. Ogasawara | Hirohito Ishigaki | Misako Nakayama | Shintaro Shichinohe | M. Arikata | Takaaki Kinoshita | H. Ishigaki | M. Nakayama
[1] K. To,et al. Triple combination of FDA-approved drugs including flufenamic acid, clarithromycin and zanamivir improves survival of severe influenza in mice , 2018, Archives of Virology.
[2] Tokiko Watanabe,et al. A Highly Pathogenic Avian H7N9 Influenza Virus Isolated from A Human Is Lethal in Some Ferrets Infected via Respiratory Droplets. , 2017, Cell host & microbe.
[3] Xiang-rong Zhao,et al. Genesis and Spread of Newly Emerged Highly Pathogenic H7N9 Avian Viruses in Mainland China , 2017, Journal of Virology.
[4] Catherine S. K. Cheung,et al. Anti‐inflammatory effects of adjunctive macrolide treatment in adults hospitalized with influenza: A randomized controlled trial , 2017, Antiviral research.
[5] A. Tam,et al. Efficacy of Clarithromycin‐Naproxen‐Oseltamivir Combination in the Treatment of Patients Hospitalized for Influenza A(H3N2) Infection: An Open‐label Randomized, Controlled, Phase IIb/III Trial , 2017, Chest.
[6] Y. Sakoda,et al. Comparison of pathogenicities of H7 avian influenza viruses via intranasal and conjunctival inoculation in cynomolgus macaques. , 2016, Virology.
[7] H. Suzaki,et al. Past, present and future of macrolide therapy for chronic rhinosinusitis in Japan. , 2016, Auris, nasus, larynx.
[8] Y. Sakoda,et al. Emergence of H7N9 Influenza A Virus Resistant to Neuraminidase Inhibitors in Nonhuman Primates , 2015, Antimicrobial Agents and Chemotherapy.
[9] H. Kubo,et al. Additional treatment with clarithromycin reduces fever duration in patients with influenza. , 2014, Respiratory investigation.
[10] Y. Kawaoka,et al. Efficacy of Repeated Intravenous Administration of Peramivir against Highly Pathogenic Avian Influenza A (H5N1) Virus in Cynomolgus Macaques , 2014, Antimicrobial Agents and Chemotherapy.
[11] H. Kitano,et al. Disease Severity Is Associated with Differential Gene Expression at the Early and Late Phases of Infection in Nonhuman Primates Infected with Different H5N1 Highly Pathogenic Avian Influenza Viruses , 2014, Journal of Virology.
[12] Y. Kawaoka,et al. Protective Efficacy of Passive Immunization with Monoclonal Antibodies in Animal Models of H5N1 Highly Pathogenic Avian Influenza Virus Infection , 2014, PLoS pathogens.
[13] K. Yanagihara,et al. Efficacy of Combination Therapy with Oseltamivir Phosphate and Azithromycin for Influenza: A Multicenter, Open-Label, Randomized Study , 2014, PloS one.
[14] Y. Kawaoka,et al. Protection against H5N1 Highly Pathogenic Avian and Pandemic (H1N1) 2009 Influenza Virus Infection in Cynomolgus Monkeys by an Inactivated H5N1 Whole Particle Vaccine , 2013, PloS one.
[15] S. Kudoh,et al. Use of macrolides in the 2009 H1N1 virus infection outbreak: a survey of general practices in Japan. , 2013, Respiratory investigation.
[16] H. Kido,et al. Immunomodulator Clarithromycin Enhances Mucosal and Systemic Immune Responses and Reduces Re-Infection Rate in Pediatric Patients with Influenza Treated with Antiviral Neuraminidase Inhibitors: A Retrospective Analysis , 2013, PloS one.
[17] Noriko Kishida,et al. Characterization of H7N9 influenza A viruses isolated from humans , 2013, Nature.
[18] Takashi Suzuki,et al. Influenza virus utilizes N-linked sialoglycans as receptors in A549 cells. , 2013, Biochemical and biophysical research communications.
[19] M. Imai,et al. Characterization of neuraminidase inhibitor‐resistant influenza A(H1N1)pdm09 viruses isolated in four seasons during pandemic and post‐pandemic periods in Japan , 2013, Influenza and other respiratory viruses.
[20] Jie Dong,et al. Human Infection with a Novel Avian-Origin Influenza A (H7N9) Virus. , 2018 .
[21] Semicyuc,et al. Macrolide-based regimens in absence of bacterial co-infection in critically ill H1N1 patients with primary viral pneumonia , 2013, Intensive Care Medicine.
[22] H. Kido,et al. Oral Clarithromycin Enhances Airway Immunoglobulin A (IgA) Immunity through Induction of IgA Class Switching Recombination and B-Cell-Activating Factor of the Tumor Necrosis Factor Family Molecule on Mucosal Dendritic Cells in Mice Infected with Influenza A Virus , 2012, Journal of Virology.
[23] H. Mukae,et al. Clarithromycin has limited effects in non-elderly, non-severe patients with seasonal influenza virus A infection. , 2012, The Journal of infection.
[24] Eiryo Kawakami,et al. Frequency of drug-resistant viruses and virus shedding in pediatric influenza patients treated with neuraminidase inhibitors. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[25] Yukiko Muramoto,et al. Pathogenicity of highly pathogenic avian H5N1 influenza A viruses isolated from humans between 2003 and 2008 in northern Vietnam , 2010, The Journal of general virology.
[26] Ryo Takano,et al. Characterization of Oseltamivir-Resistant 2009 H1N1 Pandemic Influenza A Viruses , 2010, PLoS pathogens.
[27] B. Rubin,et al. Mechanisms of Action and Clinical Application of Macrolides as Immunomodulatory Medications , 2010, Clinical Microbiology Reviews.
[28] L. Gubareva,et al. Detection of E119V and E119I Mutations in Influenza A (H3N2) Viruses Isolated from an Immunocompromised Patient: Challenges in Diagnosis of Oseltamivir Resistance , 2010, Antimicrobial Agents and Chemotherapy.
[29] R. Nagatomi,et al. Clarithromycin Inhibits Type A Seasonal Influenza Virus Infection in Human Airway Epithelial Cells , 2010, Journal of Pharmacology and Experimental Therapeutics.
[30] H. Togari,et al. Boost of mucosal secretory immunoglobulin A response by clarithromycin in paediatric influenza , 2009, Respirology.
[31] R. Nagatomi,et al. Macrolide antibiotics inhibit respiratory syncytial virus infection in human airway epithelial cells. , 2009, Antiviral research.
[32] D. Kelvin,et al. Macrolides for the treatment of severe respiratory illness caused by novel H1N1 swine influenza viral strains. , 2009, Journal of infection in developing countries.
[33] Lynnette Brammer,et al. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. , 2009, JAMA.
[34] R. Wunderink,et al. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia , 2009, European Respiratory Journal.
[35] C. Roussos,et al. Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[36] J. Rello,et al. Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock* , 2007, Critical care medicine.
[37] Yoshihiro Kawaoka,et al. oseltamivir: descriptive study , 2022 .
[38] E. Gabazza,et al. In vivo and in vitro effects of macrolide antibiotics on mucus secretion in airway epithelial cells. , 2003, American journal of respiratory and critical care medicine.
[39] S. Ishizuka,et al. Erythromycin inhibits rhinovirus infection in cultured human tracheal epithelial cells. , 2002, American journal of respiratory and critical care medicine.
[40] T. Fukui,et al. Effect of maclorides on duration and resolution of symptoms and complication of pneumonia in children with influenza. , 2002, Journal of Nippon Medical School = Nippon Ika Daigaku zasshi.
[41] S. Kudoh,et al. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. , 1998, American journal of respiratory and critical care medicine.
[42] H. Maeda,et al. Therapeutic effect of erythromycin on influenza virus-induced lung injury in mice. , 1998, American journal of respiratory and critical care medicine.
[43] M. Rosenthal,et al. Long-term azithromycin may improve lung function in children with cystic fibrosis , 1998, The Lancet.